Rapid Communication
Copyright ©2007 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2007; 13(39): 5267-5272
Published online Oct 21, 2007. doi: 10.3748/wjg.v13.i39.5267
Serum transforming growth factor-β1 level reflects disease status in patients with esophageal carcinoma after radiotherapy
Su-Ping Sun, Ye-Ning Jin, Hong-Peng Yang, Yi Wei, Zhao Dong
Su-Ping Sun, Hong-Peng Yang, Department of Radiation Oncology, Xuzhou Third Hospital and Xuzhou Cancer Hospital-Affiliated Hospital of Jiangsu University, Xuzhou 221005, Jiangsu Province, China
Ye-Ning Jin, Department of Radiation Oncology, Ruijin Hospital, Shanghai 200025, China
Yi Wei, Zhao Dong, Department of Radiation Oncology, Changhai Hospital, Shanghai 200433, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Su-Ping Sun, MD, Department of Radiation Oncology, Changzhou Second Hospital-Affiliated Hospital of Nanjing Medical University, Changzhou, 213003, Jiangsu Province, China. ssp56@126.com
Telephone: +86-519-88105765 Fax: +86-519-88115560
Received: May 30, 2007
Revised: July 1, 2007
Accepted: August 24, 2007
Published online: October 21, 2007

AIM: To evaluate the relationship between changes in serum transforming growth factor β1 (TGFβ1) level and curative effect of radiotherapy (RT) in patients with esophageal carcinoma.

METHODS: Ninety patients with histologically confirmed esophageal carcinoma were enrolled. Serum samples for TGFβ1 analysis were obtained before and at the end of RT. An enzyme-linked immunosorbent assay was used to measure serum TGFβ1 level. Multivariate analysis was performed to investigate the relationship between disease status and changes in serum TGFβ1 level.

RESULTS: Serum TGFβ1 level in patients with esophageal carcinoma before RT was significantly higher than that in healthy controls (P < 0.001). At the end of RT, serum TGFβ1 level was decreased in 67.82% (59/87) of the patients. The overall survival rate at 1, 3 and 5 years was 48.28% (42/87), 19.54% (17/87) and 12.64% (11/87), respectively. Main causes of death were local failure and regional lymph node metastasis. In patients whose serum TGFβ1 level decreased after RT, the survival rate at 1, 3 and 5 years was 61.02% (36/59), 28.81% (17/59) and 18.64% (11/59), respectively. The survival rate at 1 year was 17.86% (5/28) in patients whose serum TGFβ1 level increased after RT, and all died within 18 mo (P < 0.01).

CONCLUSION: Serum TGFβ1 level may be a useful marker for monitoring disease status after RT in patients with esophageal carcinoma.

Keywords: Esophageal carcinoma, Prognosis, Radio-therapy, TGFβ1